1-20 of 303
Shaji K. Kumar
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Impact of cytogenetic abnormalities on the risk of disease progression in solitary bone plasmacytomas

Clinical Trials & Observations
Udit Yadav, Shaji K. Kumar, Linda B. Baughn, Angela Dispenzieri, Patricia Greipp, Rhett Ketterling, Dragan Jevremovic, Francis K. Buadi, David Dingli, Martha Q. Lacy, Rafael Fonseca, P. Leif Bergsagel, Sikander Ailawadhi, Vivek Roy, Ricardo Parrondo, Taimur Sher, Suzanne R. Hayman, Prashant Kapoor, Nelson Leung, Joselle Cook, Moritz Binder, Eli Muchtar, Rahma Warsame, Taxiarchis V. Kourelis, Ronald S. Go, Yi Lin, Abhishek Seth, Scott C. Lester, William G. Breen, Robert A. Kyle, Morie A. Gertz, S. Vincent Rajkumar, Wilson I. Gonsalves
Journal: Blood
Blood (2023) 142 (22): 1871–1878.
https://doi.org/10.1182/blood.2023021187
Published: 2023
Includes: Supplemental data
Journal Articles

TET2 Down-Regulation Confers Bortezomib Resistance in Multiple Myeloma

Yun Dai, Xiaobo Liu, Ting Yang, Shaji K Kumar, Fengyan Jin
Journal: Blood
Blood (2022) 140 (Supplement 1): 4185–4186.
https://doi.org/10.1182/blood-2022-168239
Published: 2022
Journal Articles

Artificial Intelligence-Enhanced Models to Predict Light Chain Amyloidosis from Patients with Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma

Eli Muchtar, Surendra Dasari, Martha Grogan, Morie A. Gertz, Martha Q. Lacy, Francis K. Buadi, David Dingli, Taxiarchis Kourelis, Itzhak Z. Attia, Francisco Lopez-Jimenez, Dennis Murphree, Paul A. Friedman, Shaji K Kumar, Angela Dispenzieri
Journal: Blood
Blood (2022) 140 (Supplement 1): 7230–7232.
https://doi.org/10.1182/blood-2022-168119
Published: 2022
Journal Articles

A Multicenter Phase I Dose-Escalation Trial of a Novel Glutaminase Inhibitor Telaglenastat in Combination with Carfilzomib and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Wilson I. Gonsalves, Natalia Neparidze, Jacob B. Allred, Shaji K Kumar, Joel M. Reid, Geoffrey Shapiro, Brian A. Costello, Richard Piekarz, Rachid C. Baz, Srinivas Devarakonda
Journal: Blood
Blood (2022) 140 (Supplement 1): 7315–7316.
https://doi.org/10.1182/blood-2022-164966
Published: 2022
Journal Articles

A Simple Risk-Scoring Model for Estimating the Prognostic Impact of 1q Gain in Patients with Newly-Diagnosed Multiple Myeloma

Fengyan Jin, Peiyu Yang, Haimin Chen, Xinyue Liang, Weiling Xu, Shanshan Yu, Wenyang Huang, Xingchen Yi, Qiang Guo, Mengru Tian, Tingting Yue, Mengyao Li, Yingjie Zhang, Mengxue Zhang, Yurong Yan, Zhongli Hu, Shaji K Kumar, Fan Zhou, Yun Dai
Journal: Blood
Blood (2022) 140 (Supplement 1): 4360–4361.
https://doi.org/10.1182/blood-2022-168602
Published: 2022
Journal Articles

Fixed Duration Daratumumab, Ixazomib, Lenalidomide, and Dexamethasone Quadruplet for Newly Diagnosed Multiple Myeloma - MRD Negativity and Survival Outcomes

Shaji K Kumar, Betsy Laplant, Erik J Asmus, Francis K. Buadi, Wilson I. Gonsalves, Eli Muchtar, David Dingli, Melanie Ann Thompson, Ronald Go, Rahma M Warsame, Taxiarchis Kourelis, Yi L. Hwa, Amie Fonder, Miriam A. Hobbs, Martha Q. Lacy, Angela Dispenzieri, Suzanne R. Hayman, Nelson Leung, Moritz Binder, S. Vincent Rajkumar, Morie A Gertz, Prashant Kapoor
Journal: Blood
Blood (2022) 140 (Supplement 1): 10142–10143.
https://doi.org/10.1182/blood-2022-169046
Published: 2022
Journal Articles

Daratumumab Plus Lenalidomide and Dexamethasone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Maia Age Subgroup Analysis

Thierry Facon, Shaji K Kumar, Katja Weisel, Saad Usmani, Philippe Moreau, Torben Plesner, Robert Z. Orlowski, Nizar Jacques Bahlis, Supratik Basu, Hareth Nahi, Cyrille Hulin, Hang Quach, Michael O'Dwyer, Aurore Perrot, Christopher P. Venner, Noopur Raje, Mourad Tiab, Margaret Macro, Laurent Frenzel, Xavier Leleu, Huiling Pei, Robin Carson, Fredrik Borgsten, Hartmut Goldschmidt
Journal: Blood
Blood (2022) 140 (Supplement 1): 10133–10136.
https://doi.org/10.1182/blood-2022-163555
Published: 2022
Journal Articles

Current Testing Practices for t(11;14) Rearrangements in Patients with Newly Diagnosed Multiple Myeloma in the United States

Linda B. Baughn, Elizabeth S. Mearns, Michael Nixon, Vivek S. Chopra, Allicia Girvan, R. Frank Cornell, Jayeta Saxena, Bethany M. Slifko, Jordan Clark, Shaji K Kumar
Journal: Blood
Blood (2022) 140 (Supplement 1): 10114–10115.
https://doi.org/10.1182/blood-2022-158076
Published: 2022
Journal Articles

Variation in the Immune Tumor Microenvironment in Relation to Self-Reported Race in Individuals with Multiple Myeloma

Neeraj Sharma, Hongwei Tang, Huihuang Yan, Shulan Tian, Suganti Shivaram, Taxiarchis Kourelis, Shaji K Kumar, Linda B. Baughn
Journal: Blood
Blood (2022) 140 (Supplement 1): 4209–4210.
https://doi.org/10.1182/blood-2022-166744
Published: 2022
Journal Articles

Universal Updated Phase 1 Data Highlights Role of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma

Sham Mailankody, Jeffrey V. Matous, Michaela Liedtke, Surbhi Sidana, Olalekan O. Oluwole, Meera Mohan, Jose C. Cruz, Rajneesh Nath, Faiz Anwer, Adriana Rossi, Myo Htut, Shahbaz A. Malik, Srinivas Ghatta, Myles Dillon, Wendy Ying, Lynn Navale, Erin E. Karski, Arun Balakumaran, Shaji K. Kumar
Journal: Blood
Blood (2022) 140 (Supplement 1): 4620–4622.
https://doi.org/10.1182/blood-2022-158231
Published: 2022
Journal Articles

Results from the First Phase 1 Clinical Study of the B-Cell Maturation Antigen (BCMA) Nex T Chimeric Antigen Receptor (CAR) T Cell Therapy CC-98633/BMS-986354 in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Luciano J. Costa, Shaji K Kumar, Shebli Atrash, Michaela Liedtke, Gurbakhash Kaur, Benjamin A. Derman, P. Leif Bergsagel, Sham Mailankody, Philip L. McCarthy, Josiana Limones, Yanping Chen, Sharmila Das, Jerill Thorpe, Jonathan Cacciatore, Garnet Navarro, Ashley K Koegel, Michael R. Burgess, Kristen Hege, Shambavi Richard
Journal: Blood
Blood (2022) 140 (Supplement 1): 1360–1362.
https://doi.org/10.1182/blood-2022-160038
Published: 2022
Journal Articles

Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Transplant-Ineligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Clinical Assessment of Key Subgroups of the Phase 3 Maia Study

Philippe Moreau, Thierry Facon, Saad Usmani, Nizar Jacques Bahlis, Noopur Raje, Torben Plesner, Robert Z. Orlowski, Supratik Basu, Hareth Nahi, Cyrille Hulin, Hang Quach, Hartmut Goldschmidt, Michael O'Dwyer, Aurore Perrot, Christopher P. Venner, Katja Weisel, Mourad Tiab, Margaret Macro, Laurent Frenzel, Xavier Leleu, Huiling Pei, Maria Krevvata, Robin Carson, Fredrik Borgsten, Shaji K Kumar
Journal: Blood
Blood (2022) 140 (Supplement 1): 7297–7300.
https://doi.org/10.1182/blood-2022-163494
Published: 2022
Journal Articles

Health-Related Quality of Life for Frail Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide and Dexamethasone: Subgroup Analysis of MAIA Trial

Aurore Perrot, Thierry Facon, Torben Plesner, Saad Usmani, Shaji K Kumar, Nizar Jacques Bahlis, Cyrille Hulin, Robert Z. Orlowski, Hareth Nahi, Peter Mollee, Karthik Ramasamy, Murielle Roussel, Arnaud Jaccard, Michel Delforge, Lionel Karlin, Bertrand Arnulf, Ajai Chari, Huiling Pei, Niodita Gupta, Shuchita Kaila, Kathryn Matt, Katharine S. Gries, Robin Carson, Fredrik Borgsten, Katja Weisel
Journal: Blood
Blood (2022) 140 (Supplement 1): 1142–1145.
https://doi.org/10.1182/blood-2022-165524
Published: 2022
Journal Articles

Outcomes of Multiple Myeloma Patients Refractory to Standard Dose Vs Low Dose Lenalidomide

Utkarsh Goel, Charalampos Charalampous, Prashant Kapoor, Moritz Binder, Francis K. Buadi, David Dingli, Angela Dispenzieri, Amie Fonder, Morie A. Gertz, Wilson I. Gonsalves, Suzanne R. Hayman, Miriam A. Hobbs, Yi L. Hwa, Taxiarchis Kourelis, Martha Q. Lacy, Nelson Leung, Yi Lin, Rahma M Warsame, Robert A. Kyle, S. Vincent Rajkumar, Shaji K Kumar
Journal: Blood
Blood (2022) 140 (Supplement 1): 9998–9999.
https://doi.org/10.1182/blood-2022-160368
Published: 2022
Journal Articles

Persistance or Reappearance of Serum Monoclonal Protein Detected By Mass Spectrometry Is a Major Prognostic Factor in Patients with Newly Diagnosed Multiple Myeloma

Jean-Sébastien Claveau, David L Murray, Angela Dispenzieri, Prashant Kapoor, Moritz Binder, Francis K. Buadi, David Dingli, Amie Fonder, Morie A. Gertz, Wilson I. Gonsalves, Suzanne R. Hayman, Miriam A. Hobbs, Yi L. Hwa, Taxiarchis Kourelis, Martha Q. Lacy, Nelson Leung, Yi Lin, Rahma M Warsame, Robert A. Kyle, S. Vincent Rajkumar, Shaji K Kumar
Journal: Blood
Blood (2022) 140 (Supplement 1): 2347–2348.
https://doi.org/10.1182/blood-2022-167430
Published: 2022
Journal Articles

Trial in Progress: REGN5458, a BCMAxCD3 Bispecific Antibody, in a Phase Ib Multi-Cohort Study of Combination Regimens for Patients with Relapsed/Refractory Multiple Myeloma

Paula Rodríguez Otero, Nisha S. Joseph, Shaji K Kumar, Hans C. Lee, Xavier Leleu, Salomon Manier, Meletios A. Dimopoulos, María Victoria Mateos, Albert Oriol, Naresh Bumma, Weiying Gong, Pourab Roy, Karen Rodriguez Lorenc, Glenn S. Kroog, Shawn M. Sarkaria
Journal: Blood
Blood (2022) 140 (Supplement 1): 4444–4446.
https://doi.org/10.1182/blood-2022-157713
Published: 2022
Journal Articles

The Mydrug Platform Trial: Efficacy and Safety of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone in Patients with Functionally High-Risk Multiple Myeloma

Shaji K Kumar, Craig C Hofmeister, Noa Biran, Gurbakhash Kaur, Jing Christine Ye, Jeffrey A. Zonder, Umar Syed, Jennifer Yesil, Karen Woolley, George Mulligan, Hearn J. Cho
Journal: Blood
Blood (2022) 140 (Supplement 1): 4434–4435.
https://doi.org/10.1182/blood-2022-163737
Published: 2022
Journal Articles

A Phase 1 First-in-Human Study of Abbv-383, a BCMA × CD3 Bispecific T-Cell-Redirecting Antibody, As Monotherapy in Patients with Relapsed/Refractory Multiple Myeloma

Peter M. Voorhees, Anita D'Souza, Katja Weisel, David Duane Hurd, Raphael Teipel, Alfred Chung, Cesar Rodriguez, Sascha A. Tuchman, Neha Korde, Hana Safah, Orlando F. Bueno, Neil Pumford, Tanya S Rosenberg, Rajvineeth Kumar Pothacamury, Jeremy A. Ross, Akshanth R. Polepally, Shane Lee, Ziyi Jin, Chetasi Talati, Ravi Vij, Shaji K Kumar
Journal: Blood
Blood (2022) 140 (Supplement 1): 4401–4404.
https://doi.org/10.1182/blood-2022-167008
Published: 2022
Journal Articles

Performance of Glomerular Filtration Rate Estimating Equations in Cancer Patients Evaluated for Chimeric Antigen Receptor T-Cell Therapy

Jason N Barreto, Erin F Barreto, Kristin C. Mara, Andrew D. Rule, Marissa Z. Powell, Radhika Bansal, Matthew A. Hathcock, Sandra M. Herrmann, Adrienne N. Nedved, Stephen M. Ansell, N. Nora Bennani, Jonas Paludo, Patrick B. Johnston, Urshila Durani, Tyler B. Sandahl, Yucai Wang, Arushi Khurana, Hassan B. Alkhateeb, Mithun V. Shah, Prashant Kapoor, Morie A Gertz, Shaji K Kumar, David Dingli, Taxiarchis Kourelis, Rahma M Warsame, Suzanne R. Hayman, Nelson Leung, Yi Lin
Journal: Blood
Blood (2022) 140 (Supplement 1): 10942–10944.
https://doi.org/10.1182/blood-2022-164785
Published: 2022
Journal Articles

Evidence Supporting Light Chain Cast Nephropathy As a Myeloma Defining Event

Andrea Angioi, Moritz Binder, Nelson Leung, Frank Bridoux, Camille Cohen, David Dingli, Angela Dispenzieri, Parikshit Duriseti, Roberta Fenoglio, Amie Fonder, Morie A. Gertz, Ronald Go, Wilson I. Gonsalves, Suzanne R. Hayman, Miriam A. Hobbs, Yi L. Hwa, Prashant Kapoor, Bertrand Knebelmann, Taxiarchis Kourelis, Shaji K Kumar, Robert A. Kyle, Martha Q. Lacy, Nicola Lepori, Yi Lin, Shveta Motwani, Eli Muchtar, Samih Nasr, Antonello Pani, Dario Roccatello, Virginie Royal, Paul Sanders, Stephan Troyanov, Christopher P. Venner, Rahma M Warsame, Niloufarsadat Yarandi, S. Vincent Rajkumar
Journal: Blood
Blood (2022) 140 (Supplement 1): 10068–10070.
https://doi.org/10.1182/blood-2022-162754
Published: 2022